Sunovion’s TAAR1 Agonist Brings Something New To CNS Arena
‘Exciting Step Forward’?
Sunovion’s new schizophrenia candidate is generating investor attention given its first-in-class mode of action. Newly published clinical results appear to bear out its promise in a sector where there’s been limited innovation.
You may also be interested in...
Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.